A star can­cer sci­en­tist failed to dis­close in­dus­try pay­ments over the years — does that mat­ter so much?

Dur­ing the big AS­CO con­fer­ence at the be­gin­ning of last June, promi­nent Memo­r­i­al Sloan Ket­ter­ing sci­en­tist José Basel­ga had this to say about the da­ta he had col­lect­ed for an ex­per­i­men­tal PI3K drug at Roche called taselis­ib:

This is proof that tar­get­ing the PI3K path­way has an ef­fect in breast can­cer and that there are pa­tients who will ben­e­fit. To me that is in­cred­i­bly ex­cit­ing.

Roche, how­ev­er, was not near­ly so en­thu­si­as­tic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER